secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2024-11-26T23:59:59+00:00
Accession:  0001493152-24-047747
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma doses first patient at UVA Cancer Center in Phase 2 glioblastoma trial of Ropidoxuridine
--------------------------------------------------------------------------------

- First patient enrolled and dosed at UVA Cancer Center; second site after Miami Cancer Institute.
- Phase 2 trial: 40 patients randomized to 1,200 or 960 mg/day to determine optimal dose, then add 14 more.
- Trial targets IDH wild-type, methylation negative glioblastoma; median survival <12 months with only radiation.
- Ropidoxuridine has FDA Orphan Drug Designation for glioblastoma.
- Six centers conducting trial: UVA, Georgetown, John Theurer, Allegheny Health, Miami Cancer Institute.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224047747/0001493152-24-047747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224047747/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-047747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer